Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

38.69 -0.25 (-0.65%)
Streaming Delayed Price Updated: 11:38 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
2 Top Biotech Stocks to Buy Right Now
One is growing revenue. And the other may soon launch its first product. 
Via The Motley Fool
3 Cheap Pharmaceutical Stocks to Grab Now
The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus. 
Via Talk Markets
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
Sterling At Five-Year High
Today markets are mixed because of currency factors, with sterling bullishness against the dollar and the euro. 
Via Talk Markets
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients
Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers OptiNose (NASDAQ:OPTN) stock rose... 
Via Benzinga
Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
From Exelixis, Inc.
Via Business Wire
Is Exelixis a Buy?
Revenue growth will probably accelerate soon, but it might not be enough. 
Via The Motley Fool
What Investors Should Look for With Exelixis, DermTech, and Teladoc Health
All three healthcare stocks could have solid growth prospects. 
Via The Motley Fool
Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma?
Apparently, up-front capital is better than royalties on drugs the pharma doesn't have control over. 
Via The Motley Fool
Exelixis Inc (EXEL) Q1 2021 Earnings Call Transcript
EXEL earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exelixis: Q1 Earnings Insights
Shares of Exelixis (NASDAQ:EXEL) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 52.63% over the past year... 
Via Benzinga
Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021
From Exelixis, Inc.
Via Business Wire
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.